Iloperidone (Fanapt) vs Olanzapine (Zyprexa)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Iloperidone (Fanapt)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Partial signal

NCT00254202 · Phase 3 · completed

This 4-week, randomized, double-blind Phase 3 trial (Study 2 in the FANAPT label, n=604) compared iloperidone 24 mg/day with placebo and with ziprasidone as an active control in acute schizophrenia. The primary endpoint was change in PANSS total score at day 28. The FDA label states that iloperidone 24 mg/day was superior to placebo on this endpoint, so the primary was met; efficacy appeared similar to ziprasidone. Sources: CT.gov posted results and the FANAPT label (openFDA).

Next expected readout: November 2027 · NCT06961968 (registry estimate)

Reported efficacy

Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score (4 weeks): Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2). (met)

Result source: NCT00254202

Olanzapine (Zyprexa)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT03510325 · Phase 3 · completed

This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)

Result source: NCT03510325

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIloperidone (Fanapt)Olanzapine (Zyprexa)
PANSS total, change-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998
CGI-S, change—Trial running · NCT06961968—Not posted · NCT00083668
PANSS response—Trial running · NCT0696196831.7% vs 44.7%avs amisulprideNCT03510325
PSP, change—Trial running · NCT06961968—Not posted · NCT00083668
Relapse (% of patients)—Trial running · NCT06961968—Not posted · NCT00083668

PANSS total, change

Iloperidone (Fanapt)
-12 vs -7.1−4.9 vs placebowk 4 · n 283NCT00254202
1 other result
  • 1.1 vs 12.4 wk 26 · n 150 · Phase 3 · secondary NCT01291511
Olanzapine (Zyprexa)
-8.8 vs 4.5−13.3 vs placebowk 4 · n 21NCT00686998

CGI-S, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa)
—Not posted · NCT00083668

PANSS response

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa)
31.7% vs 44.7%avs amisulprideNCT03510325

PSP, change

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa)
—Not posted · NCT00083668

Relapse (% of patients)

Iloperidone (Fanapt)
—Trial running · NCT06961968
Olanzapine (Zyprexa)
—Not posted · NCT00083668
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Iloperidone (Fanapt): 4 of 4 rows · Olanzapine (Zyprexa): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIloperidone (Fanapt)Olanzapine (Zyprexa)
Dropout rate
34.6%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
51.3%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
30.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
31.5%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
18.8%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
12.5%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
13.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
6.7%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
63.4%Olanzapine/Intense Behavioral Weigb
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
55.9%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
38.2%
NCT00190749 · Phase 4 · registry result, not featured evidence
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
22%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
34.2%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
31.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
18.2%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
14.5%Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
—Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
10.4%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
15%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.9%Olanzapine/Intense Behavioral Weigb
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
18.6%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00190749 · Phase 4 · registry result, not featured evidence
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—
NCT00797277 · Phase 3 · registry result, not featured evidence
4%Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
10.5%Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
5.5%Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
4.5%
NCT00686998 · Phase 2 · registry result, not featured evidence
—Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
—Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
—3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
—Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Serious AEs
0.7%a
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 24 more results
—Iloperidone
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone (Cross-titration and S
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
4%Iloperidone (Relapse-prevention Ph
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
3.3%Iloperidone Gradual Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
2.7%Iloperidone Immediate Switch
NCT01207414 · Phase 4 · registry result, not featured evidence
—625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%625 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%500 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
14.3%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
7.1%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
—250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%250 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%125 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
0%50 mg
NCT01348100 · Phase 1/2 · registry result, not featured evidence
19.8%Olanzapine/Intense Behavioral Weigb
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
12.7%Olanzapine/Standard Behavioral Wei
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT00190749 · Phase 4 · registry result, not featured evidence
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
0%
NCT00797277 · Phase 3 · registry result, not featured evidence
—Olanzapine
NCT00401973 · Phase 3 · registry result, not featured evidence
—Olanzapine + Amantadine
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
—Olanzapine + Metformin
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00686998 · Phase 2 · registry result, not featured evidence
0%Cohort 1: Olanzapine (Fast-D)
NCT06319170 · Phase 1 · registry result, not featured evidence
3.2%Cohort 2: Olanzapine (To-be-market
NCT06319170 · Phase 1 · registry result, not featured evidence
0%Cohort 3: Olanzapine (Slow-C)
NCT06319170 · Phase 1 · registry result, not featured evidence
0%3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
25%0.3 mg
NCT00512070 · Phase na · registry result, not featured evidence · combination
5.9%Olanzapine Only
NCT00512070 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
headache 20.3% (placebo 19.7%)
dizziness 17% (placebo 7.5%)
sedation 12.7% (placebo 8.2%)
NCT00254202 · Phase 3 · monotherapy · Schizophrenia · phase 3
show 18 more results
dizziness 11.6% (placebo 2.7%)
somnolence 8.3% (placebo 0%)
dry mouth 6.8% (placebo 0%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dizziness 2.6% (placebo 2.7%)
headache 2% (placebo 3.3%)
insomnia 2% (placebo 4.7%)
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
dry mouth 17.9%
dizziness 17.5%
somnolence 14.2%
NCT01207414 · Phase 4 · registry result, not featured evidence
dizziness 22.3%
dry mouth 20.8%
insomnia 9.6%
NCT01207414 · Phase 4 · registry result, not featured evidence
625 mg
injection site pain 66.7%
injection site induration 60%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
625 mg
headache 20%
nasal congestion 20%
anxiety 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
injection site pain 60%
injection site induration 26.7%
injection site swelling 20%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
500 mg
nasal congestion 33.3%
constipation 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
back pain 7.1%
constipation 7.1%
headache 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
insomnia 20%
headache 13.3%
somnolence 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
constipation 14.3%
headache 14.3%
anxiety 7.1%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
headache 33.3%
insomnia 33.3%
dyspepsia 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
injection site pain 53.3%
headache 26.7%
nasal congestion 26.7%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
250 mg
nasal congestion 40%
headache 26.7%
oropharyngeal pain 13.3%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
pruritus 50%
throat irritation 50%
upper respiratory tract infection 50%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
125 mg
constipation 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
blood creatine phosphokinase increased 50%
agitation 0%
akathisia 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
50 mg
dizziness 50%
headache 50%
agitation 0%
NCT01348100 · Phase 1/2 · registry result, not featured evidence
b
somnolence 23.8%
weight increased 20.8%
headache 19.8%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 14 more results
weight increased 30.4%
headache 18.6%
somnolence 18.6%
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
weight increased 16.2%
headache 10.3%
sedation 10.3%
NCT00190749 · Phase 4 · registry result, not featured evidence
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
drowsiness 8.1%
dizziness 2.7%
NCT00797277 · Phase 3 · registry result, not featured evidence
insomnia 10%
somnolence 8%
increased appetite 6%
NCT00401973 · Phase 3 · registry result, not featured evidence
somnolence 6.6%
dry mouth 5.3%
insomnia 5.3%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.7%
somnolence 11%
nausea 6.8%
NCT00401973 · Phase 3 · registry result, not featured evidence · combination
weight increased 40.9% (placebo 0%)
increased appetite 18.2% (placebo 2.4%)
somnolence 18.2% (placebo 2.4%)
NCT00686998 · Phase 2 · registry result, not featured evidence
injection site irritation 6.9%
injection site pain 6.9%
psychotic disorder 6.9%
NCT06319170 · Phase 1 · registry result, not featured evidence
injection site pain 9.7%
somnolence 9.7%
blood creatine phosphokinase increased 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
alanine aminotransferase increased 6.5%
aspartate aminotransferase increased 6.5%
somnolence 6.5%
NCT06319170 · Phase 1 · registry result, not featured evidence
3 mg
abnormal lab values 33.3%
decreased appetite 16.7%
depression 16.7%
NCT00512070 · Phase na · registry result, not featured evidence · combination
0.3 mg
abnormal lab values 50%
depression 25%
psychotic symptoms 25%
NCT00512070 · Phase na · registry result, not featured evidence · combination
abnormal lab values 29.4%
insomnia/sleep disturbance 23.5%
diarrhea 17.6%
NCT00512070 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 21 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Iloperidone (Fanapt)

Time to Relapse NA vs 3.25 placebo months @ 26wk
time to event · months
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-S 3 vs 3.6 placebo score @ 26wk
absolute value · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
SDS -0.2 vs 1.8 placebo score @ 26wk
absolute change · score
NCT01291511 · Phase 3 · monotherapy · Schizophrenia · phase 3
CGI-C 2.826 score @ 12wk
absolute value · score
No placebo or comparator arm
NCT01207414 · Phase 4 · registry result, not featured evidence
show 1 more result
2.824 score @ 12wk
NCT01207414 · Phase 4 · registry result, not featured evidence
CGI-S -0.8 score @ 12wk
absolute change · score
No placebo or comparator arm
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.8 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence
-0.9 score @ 12wk
Change from baseline 3 cohorts combined
NCT01207414 · Phase 4 · registry result, not featured evidence

Olanzapine (Zyprexa)

BMI 3.64 kg @ 52wk
absolute change · kg
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
2.83 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
3.36 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
2.99 kg @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-I 2.04 score @ 52wk
absolute value · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
2.29 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
Waist Circumference Change 7.22 cm @ 52wk
absolute change · cm
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
7.31 cm @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
CGI-S -2.06 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-1.74 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
-0.17 score @ 313wk
NCT00088465 · Phase 3 · registry result, not featured evidence
BPRS-C Total -28 score @ 52wk
absolute change · score
No placebo or comparator arm
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-30.96 score @ 52wk
NCT00982020 · Phase 4 · registry result, not featured evidence · combination
BPRS Total -1.98 vs -1.48 Risperidone score @ 12wk
absolute change · score
Total Score Change to Last Observation
NCT00190749 · Phase 4 · registry result, not featured evidence
CGI-S -0.22 vs -0.23 Risperidone score @ 12wk
absolute change · score
Change to last observation
NCT00190749 · Phase 4 · registry result, not featured evidence
PANSS Total 0.3 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Positive 0.21 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS Negative -0.08 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology 0.19 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence
QLS Total 6.75 score @ 330wk
absolute change · score
No placebo or comparator arm
NCT00088465 · Phase 3 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloperidone (Fanapt)'s landscape · Olanzapine (Zyprexa)'s landscape